A Considerable Setback For Cancer Trials Because Of COVID-19, IQVIA/CRI Survey Finds
Executive Summary
Patient enrollment in clinical trials for cancer drugs was "severely" affected by the COVID-19 pandemic, according to a report published in Nature Reviews Drug Discovery.
You may also be interested in...
NCI Is Being 'Flexible' With COVID-19 Clinical Trial Protocols
At ASCO symposium on cancer care during the pandemic, NCI Director Ned Sharpless notes trial accrual at NCI's National Clinical Trials Network dropped by half in March and April.
Provention Announces First Clinical Trial Delay, Others Follow As COVID-19 Concerns Persist
Rather than expose patients and others to SARS-CoV-2, Provention opted to pause a Phase III type 1 diabetes trial. Addex and Iveric have since delayed trial initiations and more studies are likely to be impacted as coronavirus concerns mount.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.